Inhibition of ERK, either pharmacologically or using the Recuperating lung decoction, reduces p-ERK levels, suppresses Nrf2 overexpression, and alleviates oxidative damage and inflammation in COPD models [52]. This evidence concerns the gene NFE2L2 and chronic obstructive pulmonary disease.